PHArmacotherapy Assessed Using Neuroprobing With TransOsseal Magnetic Stimulation

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Mar 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how anti-seizure medications (ASMs) affect brain activity in adults with epilepsy. Researchers want to see if the brain's response to a technique called transcranial magnetic stimulation (TMS) changes when patients are on their medication compared to when they are not. They will measure this brain response using a method called electroencephalography (EEG) and will check if any changes last over time. Participants will take part in two sessions: one when they start their medication and another one to six months later.

To be eligible for this study, participants must be at least 18 years old, have been prescribed ASM for their epilepsy, and be able to give written consent. However, those with certain conditions, such as having electrical implants in their head or uncontrolled psychiatric issues, will not be able to join. During the study, participants can expect to undergo non-invasive tests that measure their brain activity in relation to their medication schedule. This trial aims to improve our understanding of how ASMs work in the brain, which could lead to better treatment options for people with epilepsy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (≥ 18j) with epilepsy receiving a prescription for an anti-seizure medication for clinical reasons
• • Written informed consent
• Exclusion Criteria:
• • Presence of any electrical implants (e.g. neurostimulator or drug delivery system) or any metallic implants anywhere in the head (excluding teeth)
• • Increased intracranial pressure
• • Uncontrolled psychiatric disorder
• • Use of any kind of drug or alcohol, nicotine allowed
• • For female participants: If pregnancy cannot be ruled out with sufficient certainty, a pregnancy test (urine) will be carried out before using TMS
• • Inability to give consent